Goldman Sachs Maintains Buy on Versigent, Lowers Price Target to $58

Benzinga Newsdesk www.benzinga.com Negative 61.1%

Neg 61.1% Neu 0% Pos 0%

Goldman Sachs analyst Mark Delaney maintains Versigent (NYSE:VGNT) with a Buy and lowers the price target from $59 to $58.